BTIS
SRPT icon

BB&T Investment Services’s Sarepta Therapeutics SRPT Stock Holding History

BB&T Investment Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1K Buy
+9
New +$477 ﹤0.01% 1374

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BB&T Investment Services's SRPT Position: Q4 2017 in Review

BB&T Investment Services opened a new position in Sarepta Therapeutics (SRPT) in Q4 2017: 9 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1374 among its holdings.

254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • BB&T Investment Services held 9 shares of Sarepta Therapeutics worth $1K as of Q4 2017.
  • Sarepta Therapeutics was a new BB&T Investment Services position in Q4 2017.
  • Sarepta Therapeutics made up ﹤0.01% of BB&T Investment Services's portfolio in Q4 2017, its #1374 holding.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on BB&T Investment Services's 13F filing for Q4 2017, filed 15 Feb 2018.